Zynex Reorganization Plan Confirmed, Chapter 11 Exit Nears

The latest update is out from Zynex ( (ZYXIQ) ).

On March 19, 2026, the bankruptcy court confirmed Zynex’s third amended joint plan of reorganization, paving the way for the company and its affiliates to emerge from Chapter 11, which they expect to occur by March 31, 2026, subject to conditions being met. Under the plan, existing common stock—about 30.8 million shares outstanding as of January 16, 2026—will be cancelled, new common shares will be issued solely to a plan sponsor owned by DIP lenders, unsecured creditors and convertible noteholders will receive interests in a litigation trust, and a $10 million takeback debt facility and new corporate governance documents will reshape the capital structure, leaving current equity holders facing a substantial loss on their investment while priority creditors are paid in full.

The plan also provides for broad rejection of executory contracts and unexpired leases unless specifically assumed, giving the reorganized company latitude to shed or renegotiate obligations as it restructures operations. Zynex cautioned that trading in its securities during the Chapter 11 process is highly speculative, noting that market prices may not reflect actual recoveries in the case and underscoring the heightened risk and uncertainty facing shareholders and other stakeholders as the restructuring is implemented.

The most recent analyst rating on (ZYXIQ) stock is a Hold with a $0.05 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXIQ Stock Forecast page.

Spark’s Take on ZYXIQ Stock

According to Spark, TipRanks’ AI Analyst, ZYXIQ is a Underperform.

The score is driven primarily by distressed financial performance (declining revenue, losses, negative equity/leverage risk) and strongly bearish technicals (price far below moving averages and negative MACD). Valuation is not meaningfully supportive due to negative earnings and no dividend, while the earnings call outlines remediation efforts but confirms significant ongoing financial strain.

To see Spark’s full report on ZYXIQ stock, click here.

More about Zynex

Zynex, Inc. operates in the healthcare sector and has historically focused on medical technology, though the filing emphasizes its status as a debtor under U.S. Chapter 11 proceedings rather than detailing its product lines or specific markets. The company and certain subsidiaries are currently navigating a court-supervised restructuring process in the U.S. Bankruptcy Court for the Southern District of Texas.

On March 19, 2026, the bankruptcy court confirmed Zynex’s third amended joint plan of reorganization, paving the way for the company and its affiliates to emerge from Chapter 11, which they expect to occur by March 31, 2026, subject to conditions being met. Under the plan, existing common stock—about 30.8 million shares outstanding as of January 16, 2026—will be cancelled, new common shares will be issued solely to a plan sponsor owned by DIP lenders, unsecured creditors and convertible noteholders will receive interests in a litigation trust, and a $10 million takeback debt facility and new corporate governance documents will reshape the capital structure, leaving current equity holders facing a substantial loss on their investment while priority creditors are paid in full.

The plan also provides for broad rejection of executory contracts and unexpired leases unless specifically assumed, giving the reorganized company latitude to shed or renegotiate obligations as it restructures operations. Zynex cautioned that trading in its securities during the Chapter 11 process is highly speculative, noting that market prices may not reflect actual recoveries in the case and underscoring the heightened risk and uncertainty facing shareholders and other stakeholders as the restructuring is implemented.

Average Trading Volume: 876,622

Technical Sentiment Signal: Sell

Current Market Cap: $2.17M

Learn more about ZYXIQ stock on TipRanks’ Stock Analysis page.